These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 28496550)

  • 41. Comparative effectiveness of oral antidiabetic drugs in preventing cardiovascular mortality and morbidity: A network meta-analysis.
    Lee G; Oh SW; Hwang SS; Yoon JW; Kang S; Joh HK; Kwon H; Kim J; Park D
    PLoS One; 2017; 12(5):e0177646. PubMed ID: 28542373
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of glucose-lowering therapies on risk of stroke in type 2 diabetes.
    Bonnet F; Scheen AJ
    Diabetes Metab; 2017 Sep; 43(4):299-313. PubMed ID: 28522196
    [TBL] [Abstract][Full Text] [Related]  

  • 43. SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy.
    Kawanami D; Matoba K; Takeda Y; Nagai Y; Akamine T; Yokota T; Sango K; Utsunomiya K
    Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28524098
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sodium-dependent glucose transporters (SGLT) in human ischemic heart: A new potential pharmacological target.
    Di Franco A; Cantini G; Tani A; Coppini R; Zecchi-Orlandini S; Raimondi L; Luconi M; Mannucci E
    Int J Cardiol; 2017 Sep; 243():86-90. PubMed ID: 28526540
    [TBL] [Abstract][Full Text] [Related]  

  • 45. EMPA-REG OUTCOME: The Nephrologist's Point of View.
    Wanner C
    Am J Med; 2017 Jun; 130(6S):S63-S72. PubMed ID: 28526179
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sodium-Glucose Co-transporters and Their Inhibition: Clinical Physiology.
    Ferrannini E
    Cell Metab; 2017 Jul; 26(1):27-38. PubMed ID: 28506519
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial.
    Kapitza C; Dahl K; Jacobsen JB; Axelsen MB; Flint A
    Diabetologia; 2017 Aug; 60(8):1390-1399. PubMed ID: 28526920
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.
    Thrasher J
    Am J Med; 2017 Jun; 130(6S):S4-S17. PubMed ID: 28526182
    [TBL] [Abstract][Full Text] [Related]  

  • 49. EMPA-REG OUTCOME: The Endocrinologist's Point of View.
    Perreault L
    Am J Med; 2017 Jun; 130(6S):S51-S56. PubMed ID: 28526185
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Vildagliptin has the same safety profile as a sulfonylurea on bone metabolism and bone mineral density in post-menopausal women with type 2 diabetes: a randomized controlled trial.
    Vianna AGD; de Lacerda CS; Pechmann LM; Polesel MG; Marino EC; Borba VZC; Barreto FC
    Diabetol Metab Syndr; 2017; 9():35. PubMed ID: 28515791
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of glucagon-like peptide-1 receptor agonists on mortality and cardiovascular events: A comprehensive meta-analysis of randomized controlled trials.
    Monami M; Zannoni S; Pala L; Silverii A; Andreozzi F; Sesti G; Mannucci E
    Int J Cardiol; 2017 Aug; 240():414-421. PubMed ID: 28501352
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The addition of vildagliptin to metformin prevents the elevation of interleukin 1ß in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, open-label study.
    Younis A; Eskenazi D; Goldkorn R; Leor J; Naftali-Shani N; Fisman EZ; Tenenbaum A; Goldenberg I; Klempfner R
    Cardiovasc Diabetol; 2017 May; 16(1):69. PubMed ID: 28532406
    [TBL] [Abstract][Full Text] [Related]  

  • 53. GLP-1R as a Target for the Treatment of Diabetic Retinopathy: Friend or Foe?
    Simó R; Hernández C
    Diabetes; 2017 Jun; 66(6):1453-1460. PubMed ID: 28533296
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Euglycemic Diabetic Ketoacidosis With Prolonged Glucosuria Associated With the Sodium-Glucose Cotransporter-2 Canagliflozin.
    Kelmenson DA; Burr K; Azhar Y; Reynolds P; Baker CA; Rasouli N
    J Investig Med High Impact Case Rep; 2017; 5(2):2324709617712736. PubMed ID: 28634592
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes.
    Januzzi JL; Butler J; Jarolim P; Sattar N; Vijapurkar U; Desai M; Davies MJ
    J Am Coll Cardiol; 2017 Aug; 70(6):704-712. PubMed ID: 28619659
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A network meta-analysis for efficacy and safety of seven regimens in the treatment of type II diabetes.
    Wang LG; Wang H; Liu Q; Hua WC; Li CM
    Biomed Pharmacother; 2017 Aug; 92():707-719. PubMed ID: 28586742
    [TBL] [Abstract][Full Text] [Related]  

  • 57. EMPA-REG OUTCOME: The Nephrologist's Point of View.
    Wanner C
    Am J Cardiol; 2017 Jul; 120(1S):S59-S67. PubMed ID: 28606346
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of sodium-glucose cotransporter 2 inhibitors on urinary excretion of intact and total angiotensinogen in patients with type 2 diabetes.
    Yoshimoto T; Furuki T; Kobori H; Miyakawa M; Imachi H; Murao K; Nishiyama A
    J Investig Med; 2017 Oct; 65(7):1057-1061. PubMed ID: 28596160
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Non-severe Hypoglycemia Risk Difference between Sulfonylurea and Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2-I) as an Add-On to Metformin in Randomized Controlled Trials.
    Farahani P
    J Popul Ther Clin Pharmacol; 2017 May; 24(2):e32-e40. PubMed ID: 28594482
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy of Additional Canagliflozin Administration to Type 2 Diabetes Patients Receiving Insulin Therapy: Examination of Diurnal Glycemic Patterns Using Continuous Glucose Monitoring (CGM).
    Matsumura M; Nakatani Y; Tanka S; Aoki C; Sagara M; Yanagi K; Suzuki K; Aso Y
    Diabetes Ther; 2017 Aug; 8(4):821-827. PubMed ID: 28646412
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.